摘要
１９９２年１月～１９９５年５月，分别对７８例及３２例肾移植患者术后立即应用ＡＬＧ和ＯＫＴ_３，随机选择８０例术后立即应用ＣｓＡ的患者为对照组，以了解ＣｓＡ顺序用药对移植肾早期功能的影响。结果显示：ＡＬＧ组和ＯＫＴ_３组急性排斥反应（ＡＲ）发生率分别为１１．５％和１２．５％，ＣｓＡ组为２３．８％（Ｐ＜０．０５），急性肾小管坏死（ＡＴＮ）ＡＬＧ组和ＯＫＴ_３组分别为５．１％和６．３％，ＣｓＡ组为１５．１％（Ｐ＜０．０５），移植肾功能３天正常率ＡＬＧ组和ＯＫＴ_３组分别为８３．３％和６８．８％，ＣｓＡ组为５７．５％（Ｐ＜０．０５）。证实ＣｓＡ顺序用药可有效地预防ＡＲ和ＡＴＮ的发生，促进移植肾功能的早期恢复。
From Jan 1992 to May 1995,ALG, OKT_3 or CsA was administered immediately after kidney transplantation to 78,32 and 80 patients respectively.The morbidity of acute rejection was 11.5%in ALG group,12.5%in OKT_3 group and 23.8% in CsA group(P<0.05).The incidence of acute tubular necrosis was 5.1%and 6.3% and 15.1%respectively(P<0.05).Normal kidney function rate within 3 days of transplantation was 83.3%,68.8% and 57.5% respectively(P< 0.05).It was claimed that the sequential use of CsA could reduce the morbidity of acute rejection and acute tubular necrosis effectively and would promote early recovery of the transplanted kidney function.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
1996年第6期341-344,共4页
Chinese Journal of Urology
